Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-Dose Gleevec in Early Chronic Phase CML
NCT00038649Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2001
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2001; status: terminated.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00038649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038649.